Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ...
Net Income: $370.4 million or $2.75 per share for the quarter ended March 31, 2025.
Revenue: $542.7 million for the quarter ended March 31, 2025.
Operating Expenses: $161.5 million for the quarter ended March 31, 2025.
Cash and Investments: $1.1 billion as of March 31, 2025.
Common Shares Outstanding: 138.1 million as of March 31, 2025.
Cash Flow from Operating Activities: $460.1 million provided during the quarter ended March 31, 2025.
Sarepta Agreement Revenue Recognition: $542.7 million recognized during the quarter ended March 31, 2025.
Future Revenue Guidance: $90 million to $125 million expected over the next 12 months from initial fixed contract revenue.
Warning! GuruFocus has detected 5 Warning Signs with ARWR.
Release Date: May 12, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is on track to launch its first commercial product, plozasiran, this year, pending regulatory approval.
The company has a strong financial position, with $1.1 billion in cash and investments, and is funded into 2028.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has a robust pipeline with multiple Phase III studies and potential launches in the coming years.
The company has secured a significant partnership with Sarepta Therapeutics, bringing in $500 million upfront and additional potential milestones.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is making progress in expanding its RNAi technology to new areas, including CNS and obesity treatments.
The biotech market remains uncertain, which could impact future funding and partnerships.
Regulatory approval for plozasiran is still pending, with a PDUFA date set for November 18, 2025.
There is competition in the triglyceride-lowering market, which could impact the commercial success of plozasiran.
The company faces challenges in patient identification and market education for its rare disease treatments.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has not yet finalized its commercialization strategy for plozasiran outside the U.S., which could delay international market entry.
Q: For INHIBNY and ALK7, how are you setting expectations for initial monotherapy and potential combo data, including changes on weight loss, body composition, and relevant biomarkers? A: James Hamilton, Chief of Discovery and Translational Medicine, stated that they are not providing guidance on expectations as this is a first-in-human study. The animal data were compelling, showing good weight loss both as a monotherapy and in combination with tirzepatide. They are particularly interested in the quality of weight loss, such as the loss of visceral fat and retention of lean muscle mass, which was observed in animal models. Initial data is expected towards the end of the year.
Q: Ahead of the plozasiran FDA review decision, how do you think about the robustness of your pancreatitis data and potential label differentiation? A: Bruce Given, Chief Operating Officer and Head of Research and Development, mentioned that they haven't had labeling negotiations with the FDA yet. They are confident in their data, which focused on confirmed pancreatitis using the AtLAA criteria, unlike Ionis, which included possible and probable cases. The focus is on achieving low triglyceride levels, which correlates with reduced pancreatitis risk.
Q: For plozasiran in SHTG, what is the expected baseline rate of acute pancreatitis in your population for SHASTA-3 and 4, and what magnitude of effect do you expect to show? A: Christopher Anzalone, President and CEO, explained that they expect to replicate Phase II results, with mean triglycerides around 850 to 900 and a placebo-adjusted change of 53% reduction. For the pancreatitis study, the baseline might be closer to the PALISADE study, around 2,000, as patients with a history of pancreatitis are more susceptible even at lower triglyceride levels.
Q: How are you thinking about advancing both ARO-ALK7 and ARO-INHBE through clinical development, and do you have interest or capacity to advance both? A: James Hamilton stated that both programs are being advanced through Phase I to assess safety, PD, and efficacy data. ARO-INHBE uses the well-vetted GalNAc technology, while ARO-ALK7 uses a new platform. They plan to choose one to move forward after reviewing the data, with potential for partnership opportunities.
Q: How are you thinking about commercialization of plozasiran ex-U.S.? Are you planning to do that by yourself or looking for a partner? A: Christopher Anzalone mentioned that they are preparing for commercialization in Europe and are open to finding partners. They believe the European markets, particularly the large four European markets and the U.K., are well-suited for commercialization of a rare disease like FCS, with limited infrastructure and resources needed to reach centers of excellence.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
36 minutes ago
- Wall Street Journal
Treasury Yields Fall Amid Concerning Labor Data, Mild Inflation
0900 ET – U.S. labor and inflation data deepen a decline in Treasury yields. Weekly jobless claims were unchanged from the previous week's upwardly revised pace, at 248,000. Economists surveyed by WSJ expected 246,000. Continuing claims, a measure of the unemployed population, was 1.96 million, the highest level since November 2021. May's wholesale price inflation was 0.1%, accelerating from April's 0.2% deflation and below consensus of a positive 0.2%. The combination of slower-than-expected inflation and concerning labor data underscores bets that the Fed may need to change its hawkish position. Yields were already declining and fell further after the data. The 10-year Treasury yield is at 4.360% and the two-year at 3.891%. ( @ptrevisani) 0614 GMT – A downside surprise in U.S. CPI data gave only a small boost to Treasurys, probably because tariff-driven price hikes still look imminent, says Capital Economics' James Reilly in a note. That said, these price hikes look discounted in markets, shielding Treasury yields from rising pressure, the senior markets economist says. 'We don't expect much upwards pressure on Treasury yields even as the inflationary impact of tariffs eventually feeds into U.S. consumer prices,' he says. Capital Economics expects core inflation to rise in coming months but it thinks that investors are already braced for a broadly similar outcome on tariffs, he says. (
CBS News
37 minutes ago
- CBS News
Governor Wes Moore to announce initiative to lower energy costs in Maryland
Amid rising energy costs, Maryland Governor Wes Moore plans to announce a new initiative to lower energy costs Thursday morning. On Jan. 1, Baltimore Gas and Electric raised rates, increasing the average residential gas bill by 9% and the electric bill by 7%. The cost of energy in Maryland continued to rise BGE customers and state leaders publicly challenged the increases, which were a part of the company's planned multi-year utility rate hikes. In February, the Baltimore City Council called on state regulators to stop the increases, which totaled $602 million over the course of three years. BGE said the increase was necessary to cover the cost of continued investments in gas and electric distribution systems. In March, City Council President Zeke Cohen led a community walk, going door to door to collect signatures on a petition that asked the Maryland Public Service Commission (PSC) to stop the hikes. Some customers experienced price hikes larger than the stated increase rates, with some residents reporting that their winter bills climbed by more than $200. In response to the hikes, lawmakers passed a bill, the Next Generation Energy Act, which aims to reduce costs by directing the Public Service Commission to reject multi-year rate hikes that don't demonstrate customer benefit, and prohibiting utilities from charging ratepayers for certain expenses like trade association memberships and private planes. Why have energy costs increased? BGE said those additional increases seen by consumers were a result of an increase in the price of natural gas and increased gas usage. Then again on June 1, BGE's electricity cost to consumers rose by $16 monthly, which the company said was due to an unexpected spike in capacity auction prices and the Talen Energy reliability-must-run (RMR) fee. When BGE announced the increase, the Maryland General Assembly wrote a letter urging federal legislators to stop the increase. They blamed PJM Interconnection, the region's power grid operator, for miscalculating the supply and demand for electricity during the capacity market auction, a competitive bidding process where power companies promise to make their electricity generation available in the future.
Fox News
37 minutes ago
- Fox News
Fate of Trump's $9.4 billion spending cut package hangs on House GOP moderates
The fate of President Donald Trump's $9.4 billion spending cuts request could rest on the shoulders of a handful of moderate House Republicans. The House of Representatives is set to consider the measure on Thursday afternoon, which cuts $8.3 billion in funds to the U.S. Agency for International Development (USAID) and just over $1 billion from the Corporation for Public Broadcasting, which routes federal funds to NPR and PBS. But at least four GOP lawmakers are known to have expressed at least some concerns about various aspects of the package. House Republican leaders have a razor-thin, three-seat majority in the chamber, which means any dissent beyond that could sink the bill. None of the four Republicans – Reps. Mark Amodei, R-Nev.; David Valadao, R-Calif.; Nicole Malliotakis, R-N.Y.; and Don Bacon, R-Neb. – have said how they will vote on the bill, however. They also all approved a procedural vote to allow for debate on the measure. But Amodei, co-chair of the Public Broadcasting Caucus, told Fox News Digital on Wednesday afternoon that he was not worried about NPR and PBS' national brands, with which he acknowledged the GOP's bias concerns, and that his fear was gutting funding to smaller local outlets that rely on federal funding to keep people informed in areas with less access. "These aren't the people that are doing editorial boards that are flipping you the bird," Amodei argued to his fellow Republicans. "They're kind of important pieces of infrastructure in their communities." Amodei, who is intimately familiar with the government funding process as a House appropriator, said "a whole bunch of red counties" depend on public broadcast funding. "It's easier for the nationals to raise money if they've got to make up for some funding they lost than it is these guys," he said. Valadao, who represents a California swing district, told Politico he was not sure if the measure would pass. He declined to elaborate on his concerns to Fox News Digital, however, and his office did not respond to a request for clarification. Meanwhile, Malliotakis told reporters on Wednesday that she met with Republican voters in her district who wanted PBS funding preserved – but that her real concern was the process. "I think that there's a lot of questions that members have regarding what programs specifically are going to be cut. This is a broad look at general accounts. We are, at the end of the day, the Congress that holds the power of the purse. We're the ones who we're supposed to be identifying where funding is going. And this gives a lot of discretion to the White House to be doing that unilaterally without Congress," Malliotakis said. "I think there's a large number of members that do have concerns about that. And whether members are going to vote yes or no is a different story in this place. But I have, certainly, reservations…and we'll see how things go." Bacon, one of three House Republicans representing a district that former Vice President Kamala Harris won in 2024, told reporters Tuesday morning that he was feeling better about the legislation after getting assurances that the foreign aid cuts would not gut money for critical medical research. He did not say whether his earlier concerns about PBS and NPR were alleviated, however, nor did he say how he would vote on the bill. Bacon told reporters last week, "It does bother me, because I have a great rapport with Nebraska Public Radio and TV." Fox News Digital reached out both to Bacon directly and to his office for clarification on his current stance. The $9.4 billion proposal is called a rescissions package, a mechanism for the White House to block congressionally approved funding it disagrees with. Once transmitted to Capitol Hill, lawmakers have 45 days to approve the rescissions proposal, otherwise it is considered rejected. Such measures only need a simple majority in the House and Senate to pass. But that's no easy feat with Republicans' thin majorities in both chambers. If passed, Republican leaders hope the bill will be the first of several rescissions packages codifying spending cuts identified by Elon Musk's Department of Government Efficiency (DOGE). Musk set out with a goal of finding $2 trillion in federal waste, but wound up identifying about $180 billion. House GOP leaders lauded the proposal during their weekly press conference on Tuesday. "These are commonsense cuts. And I think every member of this body should support it. It's a critical step in restoring fiscal sanity and beginning to turn the tides and removing fraud, waste, and abuse from our government," Speaker Mike Johnson, R-La., said.
